

In HFpEF with LVEF below normal\*, **Choose ENTRESTO® to help improve outcomes<sup>1,2,3</sup>**



### ENTRESTO REDUCED TOTAL HF HOSPITALIZATIONS AND CV DEATH<sup>1,2</sup>

In a prespecified subgroup analysis of PARAGON-HF patients with LVEF at or below the median\*

**22%** ↓

#### RRR IN COMPOSITE END POINT VS VALSARTAN

RR 0.78 (95% CI: 0.64, 0.95); ARR†3.6

At the primary end point, a composite of total (first and recurrent) HF hospitalizations and CV death, ENTRESTO did not achieve statistical significance vs valsartan (RR 0.87; 95% CI: 0.75, 1.01; P = 0.06).

### ENTRESTO REDUCED PLASMA NT-proBNP LEVELS AND WAS ASSOCIATED WITH CLINICAL BENEFIT COMPARED WITH VALSARTAN<sup>3</sup>

Among patients with EF > 40% stabilized after WHF,

**15%** ↓

#### GREATER TIME-AVERAGED REDUCTION IN THE NT-proBNP VS VALSARTAN

(ratio of change: 0.85; 95% CI: 0.73-0.999; P 1/4 0.049)

### ENTRESTO REDUCED TOTAL HF HOSPITALIZATIONS VS VALSARTAN<sup>2</sup>

Components of the Composite:

**25%** ↓

#### RRR IN TOTAL HOSPITALIZATION

RR 0.75 (95% CI: 0.60, 0.95); ARR†3.6

CV death: RR 0.99 (95% CI: 0.77, 1.26); ARR†0.1

**Choose ENTRESTO first for HF patients with LVEF below normal**

\*The median LVEF in PARAGON-HF was 57%. LVEF is a variable measure that can change over time, and the normal range differs according to patient characteristics and method of assessment. † Event rate per 100 patient-years. ARR = absolute rate reduction; BID = twice daily; CI = confidence interval; HR = hazard ratio; NYHA = New York Heart Association; RR = rate ratio; RRR = relative rate reduction; WHF = Worsening Heart Failure.

References:

1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2024.
2. US Food and Drug Administration. Novartis Cardiovascular and Special Drugs Advisory Committee Briefing Document. December 15, 2020. ENTRESTO® (sacubitril/valsartan) in chronic heart failure and preserved ejection fraction. Accessed November 3, 2021. <https://www.fda.gov/media/14437/attachment>.
3. Merz BJ, Wondol H, Hernandez AF, et al. Angiotensin-receptor inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. *J Am Coll Cardiol*. 2023;80(7):645-654. doi:10.1016/j.jacc.2023.04.019.